

Trends in Microbiology

Figure 1. Unbiased shRNA Screen in Latently Infected Jurkat JD10 Cells. In this screen, the estrogen receptor was identified as a repressor of HIV-1 latency. Three sequential rounds of sorting for GFP⁺ (HIV-infected) RFP⁺ (shRNA library) cells enabled the enrichment of candidate repressors. Genes were sequenced and clustered into signalling pathway networks. Reprinted with permission from Das *et al.* [5].

enriched. While the authors chose to further characterize the role of ER in latency, other hits could be worthy of future investigations: notably, other steroid receptors.

The role of ER in latency regulation was studied in two latency reactivation models – 2D10 cells and a quiescent effector cell latency model (called QUECEL, previously developed by the Kam group). ER agonists (E2 and diethylstilbestrol) potently repressed HIV-1 transcription, while selective ER modulators (SERMs: fulvestrant, raloxifene, and tamoxifen) enhanced the activity of a range of LRAs (TNF α , vorinostat, and IL-15), with a more pronounced effect for some combinations (such as vorinostat plus fulvestrant or tamoxifen) than for others. To explore the hypothesis that there may be gender-specific differences in the inducible HIV-1 reservoir and its response to LRAs and ER ligands, leukapheresis samples from well-matched men and women on ART were used to quantify the inducible reservoir via a novel EDITS assay. This method is an improvement on PCR-based techniques as it only amplifies late-spliced viral transcripts using nested

PCR and next-generation sequencing, thereby eliminating amplification of defective proviruses. Accordingly, the authors showed a lack of correlation between EDITS and both qPCR and digital droplet DNA assays. The EDITS assay indicated that samples from women harboured smaller inducible RNA reservoirs than did those from men, and both pre- and postmenopausal women were more responsive to combinations of SERMs plus LRAs. Further mechanistic insight via chromatin immunoprecipitation assays in primary Th17 cells demonstrated that the ER accumulates on the viral LTR upon E2 stimulation, which correlated with less occupancy by active RNA polymerase II. However, since a single male donor was used in this assay, the reproducibility, donor-specific and gender-specific effects remain to be determined.

While this paper presents some convincing evidence for the role of ER in latency regulation, a number of questions remain unanswered. For example, is the smaller inducible reservoir in women a direct consequence of E2 on HIV-1 replication, or is it due to differences in immune function? Does the androgen receptor (AR) play a role in latency regulation in men?

Nevertheless, these findings have major implications for therapeutic latency-reversing strategies in women, where viral emergence from latency is likely to be limited by exposure to fluctuating E2 levels throughout the menstrual cycle. The authors contend that widely used ER antagonists, such as tamoxifen (a therapy for hormone receptor-dependent breast cancer), could be repurposed for use in combination with available LRAs in order to address the latency problem. The paper elegantly demonstrates how high-quality basic mechanistic studies can identify novel targets for promising therapeutic advances. Indeed, these results form the mechanistic basis for a preliminary clinical trial using a vorinostat plus tamoxifen combination in HIV-positive

postmenopausal women, which we await with anticipation.

¹Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa

²Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

*Correspondence:

janet.hapgood@uct.ac.za (J.P. Hapgood).

<https://doi.org/10.1016/j.tim.2018.09.005>

References

1. Yin, C. *et al.* (2017) *In vivo* excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models. *Mol. Ther.* 25, 1168–1186
2. Rasmussen, T.A. and Lewin, S.R. (2016) Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? *Curr. Opin. HIV AIDS* 11, 394–401
3. U. MbonyeKam, J. (2016) The molecular basis for human immunodeficiency virus latency. *Annu. Rev. Virol.* 4, 261–285
4. Meditz, A.L. *et al.* (2011) Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. *J. Infect. Dis.* 203, 442–451
5. Das, B. *et al.* (2018) Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. *Proc. Natl. Acad. Sci. U. S. A.* 115, E7795–E7804
6. Hapgood, J.P. and Tomasichio, M. (2010) Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis. *Arch. Virol.* 155, 1009–1019
7. Alvarez-Carbonell, D. *et al.* (2018) The glucocorticoid receptor is a critical regulator of HIV latency in human microglial cells. *J. Neuroimmune Pharmacol.* Published online July 10, 2018. <http://dx.doi.org/10.1007/s11481-018-9798-1>
8. Szotek, E.L. *et al.* (2013) 17 β -estradiol inhibits HIV-1 by inducing a complex formation between β -catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription. *Virology* 443, 375–383
9. Katagiri, D. *et al.* (2006) Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1). *Int. Immunopharmacol.* 6, 170–181
10. Vicetti Miguel, R.D. *et al.* (2010) 17-Beta estradiol promotion of herpes simplex virus type 1 reactivation is estrogen receptor dependent. *J. Virol.* 84, 565–572

Forum

Modeling Diversity: Do Homogeneous Laboratory Strains Limit Discovery?

Clare M. Smith¹ and
Christopher M. Sassetti^{1,*}

The outcome of chronic infections is highly variable. The heterogeneous

disease outcomes in natural populations differ from genetically homogeneous infection models. Here, we use tuberculosis as a ‘case study’ to contrast the genetic landscape in natural populations with standard infection models, discussing new strategies to bridge this gap.

Mouse Models of Tuberculosis

Much of what we know of protective immunity to *Mycobacterium tuberculosis* (*Mtb*) was discovered in the mouse model. The standard mouse model of tuberculosis (TB) consists of infecting an inbred line of mouse, often C57BL/6, with a laboratory-adapted strain of the pathogen. Given the lack of genetic or environmental diversity, this interaction produces a homogeneous product; every animal becomes infected, mounts a Th1-biased T cell response, and eventually succumbs to disease. By deleting individual arms of immunity, it is clear that protection from TB in this model requires a robust T cell response and the production of interferon γ (IFN γ) since mice lacking this capacity are highly susceptible. Similarly, IFN γ production is an effective clinical diagnostic for TB, and human patients lacking genes necessary for this immune axis are highly susceptible to mycobacterial disease [1]. Thus, mice and humans share a fundamental dependence on certain immune mechanisms for immunity to TB. In fact, if only Mendelian traits influenced TB susceptibility, one could view the human and mouse systems to be highly concordant, and it would be completely appropriate to base therapeutic development on the C57BL/6 model. But how well does this genetically and phenotypically homogeneous system model TB in a naturally diverse population?

A Short Natural History of TB

The fact that only 5–10% of *Mtb*-infected individuals develop disease is often cited as evidence that the risk of developing TB

differs quantitatively between individuals. More fundamentally, pathological and immunological metrics also suggest qualitative differences in the underlying biology of disease. For example, a rich literature describes the diverse histopathological manifestations of disease, which range from the canonical necrotic granuloma to suppurative lesions or pneumonia. Similarly, while most individuals mount a Th1-biased cellular response when exposed to *Mtb*, the sensitivity of IFN γ -based diagnostics rarely surpass 80%, and increasing evidence indicates that this canonical response is not detectable in a substantial fraction of exposed individuals [2]. Together, these observations support the emerging view that human immunity to *Mtb* may be more diverse than previously appreciated, and the interaction between *Mtb* and the human host in the natural setting produces a wide spectrum of biologically diverse disease states.

While environmental factors, such as nutrition and coinfection, can influence disease risk, the development of TB is also influenced by the genetic composition of the host. Mendelian inheritance of rare loss-of-function alleles that disrupt Th1 immunity can produce severe susceptibility to mycobacterial infections. However, Mendelian inheritance does not explain the genetic influence on adult pulmonary TB, which appears to depend on a combination of more common alleles. A variety of association studies have identified host loci that influence TB risk [1]. Our understanding of these allelic variants remains incomplete, but the genes identified in these cohorts appear to function in a wider variety of pathways than those known to be involved in Mendelian immunodeficiencies.

While the establishment of a Th1-biased immunity remains prominent, regulation of disease-promoting inflammation, and alteration of the pathogen’s intracellular environment, also contribute. The variety

of implicated functions and preferential association between these variants with specific disease presentations, such as extrapulmonary TB, indicate that distinct biological processes control different manifestations of TB.

The human genetic variation described above accounts for only a portion of the complexity of the interaction between host and pathogen, as pathogen genotype accounts for some of the phenotypic diversity that remains unexplained by host genetics. Certainly, *Mtb* clinical isolates are phenotypically different, and they display different degrees of virulence in animal models [3]. However, these types of study oversimplify the contribution of pathogen genotype, which likely depends on interactions with host variants. Genome-to-genome analyses of other infection models often reveal that the effect of host polymorphisms depends on pathogen genotype [4]. Similarly, the long-term coevolution between *Mtb* and different human populations in distinct geographical locations has provided an opportunity for adaptation to geographically restricted host populations, which has been proposed to produce a ‘sympatric’ relationship between specific host and pathogen lineages [5]. While direct experimental evidence for this hypothesis is difficult to obtain, existing human genetic association studies that account for *Mtb* genotype discovered a differential association between human polymorphism and bacterial lineage [6]. Thus, in a natural population, the risk of developing TB, the specific manifestation of disease, and the underlying pathophysiology of the infection are influenced by interactions between host and pathogen genotype (Figure 1).

If the biology of the infection varies, should we not expect that the response to an intervention would be equally variable? Indeed, our experience from TB control confirms this expectation.




Figure 1. Tuberculosis (TB) Susceptibility Is a Complex Trait. The variability of TB is determined by interactions between environment, host genotype, and bacterial genotypes. In the laboratory we simplify these factors by controlling the environment, infecting a single inbred mouse strain with a laboratory-adapted strain of *Mycobacterium tuberculosis* (*Mtb*), and measuring a small number of traits that we hypothesize are important for driving overall disease (highlighted in red). While classical inbred lines of mice represent tractable experimental systems, the lack of genetic diversity and the homogeneous disease states means that we are modeling only a small component of the disease that is observed in humans.

Diagnostics, vaccines, and antibiotics perform reliably in the mouse model. However, in humans, immunodiagnostics suffer from ~20% false-negative rates, the efficacy of vaccination varies from 80% to zero in different populations, and even antibiotic therapy fails in up to 10% of patients even in well-controlled clinical trial settings [2,7]. This experience argues for more diverse model systems to understand how the heterogeneous biology of disease impacts our interventions.

Modeling Complexity

Clearly, the biological diversity of natural populations is not adequately modeled in a genetically homogeneous animal model. One solution to this problem has been the use of alternative species, such as guinea pigs, rabbits, and nonhuman primates. All of these systems have advantages and are reasonably used to reproduce disease states not found in the standard mouse model. However, while these pathologies can be modeled they remain difficult to mechanistically characterize due to the relative intractability of these systems. Furthermore, the increased expense of these systems generally precludes the interrogation of

different *Mtb* genotypes. A possible solution would be the introduction of controlled genetic diversity into the more tractable mouse model. Historically, this has been achieved through the use of classic substrains; however, these strains were not generated for diversity, and most are highly related. To overcome this lack of diversity, the mouse genetics field has invested in new model populations that have recently become available. The Collaborative Cross (CC) and Diversity Outbred (DO) panels are derived from the same eight parental mouse strains, which include wild-derived animals that were chosen for their genetic diversity. The DOs are randomized outbred animals whose small recombination intervals make them ideal for high resolution for genetic mapping [8]. The CC represent >100 recombinant inbred lines and represent homozygous mosaics of the eight parent genomes. Unlike outbred populations, the structure of the CC allows the serial evaluation of genetically identical individuals and quantification of genotype-specific effects of interventions. The DO and CC populations are beginning to be explored as infectious disease models, and have been found to

recapitulate many of extreme disease traits previously undetected in traditional mouse models for a variety of pathogens and immune traits [9]. Similarly, the susceptibility to TB in the DO panel varies dramatically and produces immunological variation correlating with lung damage and increased inflammation in human TB patients [10]. These diverse traits are recapitulated in the reproducible CC panel, allowing more in-depth studies that verify that immune responses differ in these animals, and these immune biases correlate with vaccine efficacy [11]. Together these resources represent a new strategy to introduce known and controlled genetic variation into our most tractable mammalian model of infectious disease.

Concluding Remarks and Future Perspectives

The goal of TB research is more effective interventions, and understanding the mechanisms by which genetic variation alters disease progression and treatment efficacy could play a key role in this process. In the future, additional nongenetic sources of variation, such as the microbiome composition that has strong

immunomodulatory effects [12], need to be accounted for in these models. While it is unlikely that this information can be used to ‘personalize’ treatment in the global health context, understanding why treatments fail in some individuals could still have a transformative effect, both in designing more powerful clinical trials and ultimately introducing an intervention, or combination of interventions, that is robust to genetic variation.

Acknowledgments

We thank Sarah Dunstan, Aditya Bandekar, Michael Kiritsy, and Micah Belew for pivotal intellectual contributions. The authors wish to note that due to the format of this article, not all pertinent references could be included. This work was supported by grants to C.M. Smith from the Charles King Foundation and to C.M. Sasseti from the NIH (AI132130).

¹Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605, USA

*Correspondence:

Christopher.Sasseti@umassmed.edu (C.M. Sasseti).

<https://doi.org/10.1016/j.tim.2018.08.002>

References

1. Abel, L. *et al.* (2018) Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. *Lancet Infect. Dis.* 18, e64–e75
2. Mazurek, G.H. *et al.* (2010) Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection – United States, 2010. *MMWR* 59, 1–25
3. Hernández-Pando, R. *et al.* (2012) Use of mouse models to study the variability in virulence associated with specific genotypic lineages of *Mycobacterium tuberculosis*. *Infect. Genet. Evol.* 12, 725–731
4. Ansari, M.A. *et al.* (2017) Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. *Nat. Genet.* 49, 666–673
5. Gagneux, S. *et al.* (2006) Variable host–pathogen compatibility in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. U. S. A.* 103, 2869–2873
6. Caws, M. *et al.* (2008) The influence of host and bacterial genotype on the development of disseminated disease with *Mycobacterium tuberculosis*. *PLoS Pathog.* 4, e1000034
7. Abubakar, I. *et al.* (2013) Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guérin vaccination against tuberculosis. *Health Technol. Assess.* 17, 1–372–v–vi
8. Bogue, M.A. *et al.* (2015) Collaborative Cross and Diversity Outbred data resources in the Mouse Phenome Database. *Mamm. Genome* 26, 511–520
9. Maurizio, P.L. and Ferris, M.T. (2016) The Collaborative Cross resource for systems genetics research of infectious diseases. In *Systems Genetics* (Schughart, K. and Williams, R.W., eds), pp. 579–596, Springer
10. Kramnik, I. and Beamer, G. (2016) Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. *Semin. Immunopathol.* 38, 221–237
11. Smith, C.M. *et al.* (2016) Tuberculosis susceptibility and vaccine protection are independently controlled by host genotype. *mBio* 7, e01516-16
12. Rosshart, S.P. *et al.* (2017) Wild mouse gut microbiota promotes host fitness and improves disease resistance. *Cell* 171, 1015–1028.e13